All In Biotech

Drug Trial Radar · NCT02287779

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects

Last checked: Nov 19, 2026Latest source record: Mar 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

84

Actual

Start

Jan 19, 2015

Primary completion

Jun 19, 2015

Study completion Jun 19, 2015

Sponsor

Lead sponsor
Mirum Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Nov 11, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.

Conditions

  • Non-Alcoholic Steatohepatitis

Interventions

  • SHP626Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard HematologyTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Fat Soluble Vitamins (Vitamin A, D, & E)Time frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Lipid PanelTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  4. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Thyroid Hormone PanelTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  5. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to CoagulationTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard ChemistryTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Urinalysis ParametersTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  8. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital SignsTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  9. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Electrocardiogram (12-lead)Time frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs)Time frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
  11. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Who Discontinued From the StudyTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Orleans Center for Clinical Research

    Knoxville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.